SCHEMBL4806950

SCHEMBL4806950

COc1ccc2nc(C(=O)O)[nH]c2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.67
PIN1 Q13526 2/20 0.65
KDM4E B2RXH2 2/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
MAPT P10636 1/20 0.60
RXFP1 Q9HBX9 1/20 0.60
NPC1 O15118 3/20 0.56
ALDH1A1 P00352 3/20 0.56
RAB9A P51151 2/20 0.56
TP53 P04637 2/20 0.56
HPGD P15428 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
TSHR P16473 1/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
HSD17B10 Q99714 1/20 0.56
CYP1A2 P05177 3/20 0.55
CYP2E1 P05181 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17742733 0.88 EGLN1 (0.64) EGLN1KDM4EMEN1KMT2AMAPT
SCHEMBL4826512 0.88 EGLN1 (0.53) EGLN1PIN1KDM4EMEN1KMT2A
SCHEMBL7153789 0.86 EGLN1 (0.62) EGLN1KDM4EMEN1KMT2AMAPT
SCHEMBL22013219 0.84 EGLN1 (0.60) EGLN1KDM4EMEN1KMT2AMAPT
SCHEMBL4651345 0.84 EGLN1 (0.60) EGLN1PIN1KDM4EMEN1KMT2A
SCHEMBL13343644 0.82 KDM4E (0.67) EGLN1KDM4EMAPTALDH1A1HPGD
SCHEMBL4310717 0.81 EGLN1 (1.00) EGLN1KDM4EMEN1KMT2AMAPT
SCHEMBL3639932 0.81 RUNX1 (0.59) EGLN1PIN1SMN1; SMN2CHEK2
SCHEMBL20495301 0.80 PRKAG1 (0.53) EGLN1PIN1KDM4EMEN1KMT2A
SCHEMBL5509574 0.79 PIN1 (1.00) PIN1KMT2ANPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300276-A1 Heterocyclic Carboxylic Acide Amide Derivatives RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-12-04 US disclosed
US-7378431-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-05-27 US disclosed
US-7375116-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-05-20 US disclosed
US-7365083-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-04-29 US disclosed
US-7361670-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-04-22 US disclosed
EP-1771437-A1 NEW HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2007-04-11 EP disclosed
WO-2006010969-A1 NEW HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-02-02 WO disclosed
US-20050159451-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-07-21 US disclosed
US-6919355-B2 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2005-07-19 US disclosed
US-20050113359-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-05-26 US disclosed
US-20050113361-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-05-26 US disclosed
US-20050113360-A1 Amide derivatives as NMDA receptor antagonists HORVATH CSILLA (HU) 2005-05-26 US disclosed
US-20030199552-A1 Amide derivatives as NMDA receptor antagonists RICHTER GEDEON VEGYESZETI GYAR RT. 2003-10-23 US disclosed
EP-1328514-A1 AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2003-07-23 EP disclosed
WO-2002034718-A1 AMIDE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2002-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113361-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B EGLN1 1315/4885PIN1 3851/4885KDM4E 934/4885
US-20050113360-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B EGLN1 1383/4885PIN1 3023/4885KDM4E 1346/4885
US-20050159451-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B EGLN1 1797/4885PIN1 3190/4885KDM4E 1242/4885
US-20080300276-A1 Heterocyclic Carboxylic Acide Amide Derivatives HCAR2, GRIN1, HCAR1 EGLN1 2097/4885PIN1 2459/4885KDM4E 1258/4885
US-20050113359-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2B EGLN1 1335/4885PIN1 3970/4885KDM4E 885/4885
US-20030199552-A1 Amide derivatives as NMDA receptor antagonists GRIN1, GRIN3A, GRIN2C EGLN1 605/4885PIN1 4306/4885KDM4E 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.